FDA, page-88

Well, the FA are certainly taking this down to the line, as is their right.
Of course, it hasn't done much to ease the nerves of 'holders'.

I, like many, have re-visited most aspects of the Phase 3 trial, from the trial structure, p-values, the 'diarrhea challenge', etc, etc.

Obviously nobody can be totally confident .. we all know the FDA has made some 'surprise decisions' in the past. But having said
that, to me, it will be an absolute shock if we don't achieve approval.

The Lilac extension was probably a master stroke on Acadia's part, even though Lavender met both primary endpoints.

I cannot even imagine the reaction of the whole Rett community if they don't get this treatment .... one that CLEARLY provides
so many benefits.

All I can say is ... may sanity prevail.

Good luck NEU, Margaret, Rett's families, and all holders. I believe we have got this.

Of course, just the opinion of one very long term holder.